Document Detail

Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma.
MedLine Citation:
PMID:  20683966     Owner:  NLM     Status:  MEDLINE    
CONCLUSION: These results strongly suggest that EGCG can inhibit CBR1 activity and enhance the effectiveness and decrease the cardiotoxicity of the anticancer drug DNR. These findings also indicate that a combination of EGCG and DNR might represent a novel approach for hepatocellular carcinoma therapy or chemoprevention.
Weixue Huang; Liya Ding; Qiang Huang; Hairong Hu; Shan Liu; Xianmei Yang; Xiaohui Hu; Yongjun Dang; Suqin Shen; Jie Li; Xiaona Ji; Songmin Jiang; Jun O Liu; Long Yu
Related Documents :
9713496 - Parallel functional and immunological detection of human multidrug resistance proteins,...
19550116 - Reversal effect of pi3-k inhibitor ly294002 on p-glycoprotein-mediated multidrug resist...
19838926 - Macelignan: a new modulator of p-glycoprotein in multidrug-resistant cancer cells.
16273216 - Voacamine, an alkaloid extracted from peschiera fuchsiaefolia, inhibits p-glycoprotein ...
17956356 - Inhibitory effect of lycopene on pdgf-bb-induced signalling and migration in human derm...
18609596 - Dissolution of sulphur particles by thiobacillus ferrooxidans: substrate for unattached...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  52     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-04     Completed Date:  2010-09-07     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  703-14     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alcohol Oxidoreductases / antagonists & inhibitors*
Antibiotics, Antineoplastic / therapeutic use
Anticarcinogenic Agents / pharmacology*,  therapeutic use*
Carcinoma, Hepatocellular / drug therapy*,  enzymology*
Catechin / analogs & derivatives*,  pharmacology,  therapeutic use
Daunorubicin / therapeutic use
Liver Neoplasms / drug therapy*,  enzymology*
Tumor Cells, Cultured
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Anticarcinogenic Agents; 8R1V1STN48/Catechin; BQM438CTEL/epigallocatechin gallate; EC 1.1.-/Alcohol Oxidoreductases; EC protein, human; ZS7284E0ZP/Daunorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  CXC receptor-2 knockout genotype increases X-linked inhibitor of apoptosis protein and protects mice...
Next Document:  Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontr...